Basic Information
SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML
INJECTION, SOLUTION
Regulatory Information
SIN16338P
October 1, 2021
Prescription Only
Therapeutic
SUBCUTANEOUS
August 10, 2023
May 30, 2025
XL04AC18
Company Information
Active Ingredients
Strength: 150mg/mL
Detailed Information
Contraindications
**4\. CONTRAINDICATIONS** SKYRIZI is contraindicated in patients with a history of serious hypersensitivity reaction to risankizumab or any of the excipients listed in section 15.2 _(see_ **WARNINGS AND PRECAUTIONS** – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_ _)._ Clinically important active infections (e.g. active tuberculosis, see section 5.2 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_).
Indication Information
**2\. INDICATIONS** **2.1 Plaque Psoriasis** SKYRIZI is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. **2.2 Psoriatic Arthritis** SKYRIZI is indicated for the treatment of active psoriatic arthritis in adults who have an inadequate response or who have been intolerant to at least one prior disease-modifying antirheumatic drug (DMARD) therapy.